Pluri Inc Dossier
Qualitative Analysis
Business overview
Pluri Inc. (formerly Pluristem Therapeutics Inc.) is an innovative, clinical-stage biotechnology company based in Haifa, Israel, that leverages a patented 3D cell expansion technology platform to develop placenta-based cell therapy product candidates. The company's proprietary platform enables the precise, large-scale cultivation of cells in controlled bioreactor environments. Pluri has expanded its strategic focus beyond traditional regenerative medicine (such as its PLX-PAD and PLX-R18 therapeutic candidates) into a collaborative network of diverse business verticals. These include PluriCDMO (contract development and manufacturing services), PluriAgtech (applying cell-based technologies to agriculture), and foodtech ventures such as its majority-owned subsidiaries Ever After Foods (cultivated meat technology), Kokomodo (cellular agriculture for sustainable cacao production), and Coffeesai (cell-based coffee).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launching flagship regenerative aesthetic products, Regenativo+ and Placento+, in the U.S. market following completed cosmetic product listings.
Expected impact: Enables entry into the professional regenerative aesthetics and longevity channels, targeting a market projected to reach $90 billion by 2030.
Offering contract development and manufacturing services leveraging Pluri's proprietary 3D cell expansion platform to early preclinical and late-stage clinical clients.
Expected impact: Generates early-stage service revenues and non-dilutive capital while validating the scalability of Pluri's bioprocessing capabilities.
Developing cell-based alternatives to traditional agricultural products, including cultivated meat, cacao, and coffee, through subsidiaries and joint ventures.
Expected impact: Addresses global challenges like food security and climate resilience by commercializing mass-scale, cost-effective cell-cultured food ingredients.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire a 71% majority stake in Kokomodo, an innovative startup utilizing cellular agriculture to produce climate-resilient, high-quality cacao directly from plant cells.
Financial impact: Settled through the issuance of 976,139 Pluri common shares, expanding Pluri's reach into the global cacao market valued at $13.5 billion in 2023.
Strategic Partnerships
Ever After Foods (Pluri's joint venture with Tnuva) partnered with Swiss manufacturing giant Bühler to jointly develop and deploy commercial-scale cultivated meat production systems.
Terms: Collaborative development and deployment of manufacturing equipment designed to reduce production costs and bioreactor sizing requirements by up to 10x.
PluriCDMO completed the first phase of a program with Resbiomed to apply Pluri's placenta-derived bioprocessing capabilities for scalable production of extracellular-matrix-based biomaterials containing natural human collagen.
Terms: Fee-for-service CDMO agreement with progression to subsequent phases subject to mutually agreed scope and timelines.
Partnered with the Ukrainian biobank Hemafund to advance and stockpile Pluri's PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine.
Terms: Initial three-year term seeking to secure funding for a stockpile of 12,000 doses, potentially generating over $100 million in revenue for both parties.